SCHEMBL25368623

SCHEMBL25368623

CC(C)Oc1cccc(NC(=O)c2csc(C(=O)Nc3cccc(NS(C)(=O)=O)c3)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHX9 Q08211 1/20 0.50
▸ PLAU P00749 3/20 0.47
▸ F2 P00734 1/20 0.47
▸ PLG P00747 1/20 0.47
▸ PLAT P00750 1/20 0.47
▸ KLKB1 P03952 1/20 0.47
▸ PRSS1 P07477 1/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ LMNA P02545 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ HPGD P15428 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ USP36 Q9P275 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30543904 1.00 DHX9 (0.50) DHX9PLAUF2PLGPLAT
SCHEMBL25368128 0.94 EPHX2 (0.48) DHX9PLAUF2PLGPLAT
SCHEMBL25369870 0.89 MRGPRX1 (0.46) DHX9MEN1KMT2ALMNAMAPT
SCHEMBL25368459 0.87 NPC1 (0.52) DHX9LMNAMAPTHPGDSMN1; SMN2
SCHEMBL30543864 0.87 NPC1 (0.52) DHX9LMNAMAPTHPGDSMN1; SMN2
SCHEMBL30543946 0.87 DHX9 (0.53) DHX9MEN1KMT2ALMNAMAPT
SCHEMBL25368280 0.87 DHX9 (0.53) DHX9MEN1KMT2ALMNAMAPT
SCHEMBL30543926 0.85 MEN1 (0.53) DHX9MEN1KMT2AMAPTMAPK1
SCHEMBL25367472 0.85 MEN1 (0.53) DHX9MEN1KMT2AMAPTMAPK1
SCHEMBL25368034 0.85 KMT2A (0.60) DHX9MEN1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US claimed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO claimed
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B DHX9 1/4885PLAU 3601/4885F2 4747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback